Compare BSRR & CCCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BSRR | CCCC |
|---|---|---|
| Founded | 1977 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.7M | 404.7M |
| IPO Year | 2001 | 2020 |
| Metric | BSRR | CCCC |
|---|---|---|
| Price | $38.78 | $4.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 6 |
| Target Price | ★ $37.00 | $12.20 |
| AVG Volume (30 Days) | 53.7K | ★ 2.9M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.93% | N/A |
| EPS Growth | 10.28 | ★ 16.45 |
| EPS | ★ 0.96 | N/A |
| Revenue | N/A | ★ $35,947,000.00 |
| Revenue This Year | $11.74 | N/A |
| Revenue Next Year | $3.63 | N/A |
| P/E Ratio | $39.15 | ★ N/A |
| Revenue Growth | N/A | ★ 1.02 |
| 52 Week Low | $26.49 | $1.36 |
| 52 Week High | $39.00 | $4.60 |
| Indicator | BSRR | CCCC |
|---|---|---|
| Relative Strength Index (RSI) | 61.41 | 62.85 |
| Support Level | $36.00 | $2.13 |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.80 | 0.37 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 97.40 | 70.09 |
Sierra Bancorp is a California-based bank holding company, which offers a range of retail and commercial banking services. it offers a wide range of deposit products and services for individuals and businesses including checking accounts, savings accounts, money market demand accounts, time deposits, retirement accounts, and sweep accounts. The company's lending activities cover real estate, commercial (including small business), mortgage warehouse, agricultural and consumer loans, and also offers commercial construction loans and multifamily and agricultural credit facilities among other types of real estate loans.
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.